HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morgan, M A Articles by Schulkin, J Search for Related Content PubMed PubMed Citation Articles by Morgan, M A Articles by Schulkin, J

Interactions of doctors with the pharmaceutical industry

¹ American College of Obstetricians and Gynecologists, Washington, DC, USA
² Carnegie Mellon University, Social and Decision Sciences, Pittsburgh, Pennsylvania, USA

Correspondence to:
M A Morgan
Research Department, American College of Obstetricians and Gynecologists, 409 12th Street, SW, Washington, DC 20024, USA; mmorgan{at}acog.org Objective: To assess the opinions and practice patterns of obstetrician-gynaecologists on acceptance and use of free drug samples and other incentive items from pharmaceutical representatives.

Methods: A questionnaire was mailed in March 2003 to 397 members of the American College of Obstetricians and Gynecologists who participate in the Collaborative Ambulatory Research Network.

Results: The response rate was 55%. Most respondents thought it proper to accept drug samples (92%), an informational lunch (77%), an anatomical model (75%) or a well-paid consultantship (53%) from pharmaceutical representatives. A third (33%) of the respondents thought that their own decision to prescribe a drug would probably be influenced by accepting drug samples. Respondents were more likely to think the average doctor’s prescribing would be influenced by acceptance of the items than theirs would be (p<0.002). Respondents who distributed drug samples to patients indicated doing so because of patients’ financial need (94%) and for their convenience (76%) and less so as a result of knowledge of the efficacy of the sample product (63%). A third (34%) of respondents agreed that interactions with industry should be more strictly regulated.

Conclusion: Obstetrician-gynaecologists largely indicated that they would act in accordance with what they think is proper regarding accepting incentive items from pharmaceutical representatives. Although accepting free drug samples was considered to be appropriate more often than any other item, samples were most commonly judged to be influential on prescribing practices. The widely accepted practice of receiving and distributing free drug samples needs to be examined more carefully.

Abbreviations: ACOG, American College of Obstetricians and Gynecologists; AMA, American Medical Association; CARN, Collaborative Ambulatory Research Network; PhRMA, Pharmaceutical Research and Manufacturers of America

This article has been cited by other articles:

				L. L. Wall and D. Brown The High Cost of Free Lunch Obstet. Gynecol., July 1, 2007; 110(1): 169 - 173. [Abstract] [Full Text] [PDF]